Dual Drug Delivery in Cochlear Implants: In Vivo Study of Dexamethasone Combined with Diclofenac or Immunophilin Inhibitor MM284 in Guinea Pigs

Cochlear implants are well established to treat severe hearing impairments. Despite many different approaches to reduce the formation of connective tissue after electrode insertion and to keep electrical impedances low, results are not yet satisfying. Therefore, the aim of the current study was to c...

Full description

Saved in:
Bibliographic Details
Main Authors: Wiebke Behrends (Author), Katharina Wulf (Author), Stefan Raggl (Author), Max Fröhlich (Author), Thomas Eickner (Author), Dana Dohr (Author), Karl-Heinz Esser (Author), Thomas Lenarz (Author), Verena Scheper (Author), Gerrit Paasche (Author)
Format: Book
Published: MDPI AG, 2023-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_e1e2b384e9b644f589112f05f8b92e01
042 |a dc 
100 1 0 |a Wiebke Behrends  |e author 
700 1 0 |a Katharina Wulf  |e author 
700 1 0 |a Stefan Raggl  |e author 
700 1 0 |a Max Fröhlich  |e author 
700 1 0 |a Thomas Eickner  |e author 
700 1 0 |a Dana Dohr  |e author 
700 1 0 |a Karl-Heinz Esser  |e author 
700 1 0 |a Thomas Lenarz  |e author 
700 1 0 |a Verena Scheper  |e author 
700 1 0 |a Gerrit Paasche  |e author 
245 0 0 |a Dual Drug Delivery in Cochlear Implants: In Vivo Study of Dexamethasone Combined with Diclofenac or Immunophilin Inhibitor MM284 in Guinea Pigs 
260 |b MDPI AG,   |c 2023-02-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics15030726 
500 |a 1999-4923 
520 |a Cochlear implants are well established to treat severe hearing impairments. Despite many different approaches to reduce the formation of connective tissue after electrode insertion and to keep electrical impedances low, results are not yet satisfying. Therefore, the aim of the current study was to combine the incorporation of 5% dexamethasone in the silicone body of the electrode array with an additional polymeric coating releasing diclofenac or the immunophilin inhibitor MM284, some anti-inflammatory substances not yet tested in the inner ear. Guinea pigs were implanted for four weeks and hearing thresholds were determined before implantation and after the observation time. Impedances were monitored over time and, finally, connective tissue and the survival of spiral ganglion neurons (SGNs) were quantified. Impedances increased in all groups to a similar extent but this increase was delayed in the groups with an additional release of diclofenac or MM284. Using Poly-L-lactide (PLLA)-coated electrodes, the damage caused during insertion was much higher than without the coating. Only in these groups, connective tissue could extend to the apex of the cochlea. Despite this, numbers of SGNs were only reduced in PLLA and PLLA plus diclofenac groups. Even though the polymeric coating was not flexible enough, MM284 seems to especially have potential for further evaluation in connection with cochlear implantation. 
546 |a EN 
690 |a dual drug delivery 
690 |a cochlear implants 
690 |a diclofenac 
690 |a immunophilin inhibitor MM284 
690 |a polymeric coating 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 15, Iss 3, p 726 (2023) 
787 0 |n https://www.mdpi.com/1999-4923/15/3/726 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/e1e2b384e9b644f589112f05f8b92e01  |z Connect to this object online.